<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1407245570
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Omeprex Plus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE,SODIUM BICARBONATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,1100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        93.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>OMEPREX PLUS is a prescription medicine called a proton pump inhibitor (PPI). OMEPREX PLUS reduces the amount of acid in your stomach.</p><p>OMEPREX PLUS is used in adults:</p><p>&bull; for 4 weeks to heal ulcers in the first part of the small bowel (duodenal ulcers). Your doctor may prescribe another 4 weeks of OMEPREX PLUS.</p><p>&bull; for up to 8 weeks for healing stomach ulcers.</p><p>&bull; for up to 4 weeks to treat heartburn and other symptoms that happen with</p><p>Gastro-oesophageal reflux disease (GORD). GORD happens when acid from the stomach backs up into the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste, or burping.</p><p>&bull; for up to 8 weeks to heal acid-related damage to the lining of the esophagus (called erosive esophagitis or EE).</p><p>&bull; to maintain healing of the esophagus. It is not known if OMEPREX PLUS is safe and effective if used longer than 12 months (1 year).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Subacute cutaneous lupus erythematosus (SCLE)</p><p>Proton pump inhibitors are associated with very frequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping this medication. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p><strong>Do not take OMEPREX PLUS if you</strong></p><p>&bull; are allergic to omeprazole or any of the other ingredients in OMEPREX PLUS (see section 6).</p><p>&bull; are allergic to any other proton pump inhibitor (PPI) medicine.</p><p>Take Special care if you</p><p>&bull; have been told that you have low magnesium, calcium, or potassium levels in your blood</p><p>&bull; have liver problems</p><p>&bull; have heart failure</p><p>&bull; have Bartter&rsquo;s syndrome (a rare kidney disorder)</p><p>&bull; have any allergies</p><p>&bull; have any other medical conditions</p><p>&bull; are pregnant or plan to become pregnant. It is not known if OMEPREX PLUS can harm your unborn baby.</p><p>&bull; are breastfeeding or plan to breastfeed. OMEPREX PLUS can pass into your breast milk and may harm your baby. You and your doctor should decide if you will take OMEPREX PLUS or breastfeed. You should not do both. Talk with your doctor about the best way to feed your baby if you take OMEPREX PLUS.</p><p><strong>Other medicines and OMEPREX PLUS</strong></p><p>Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.</p><p>This is important as using more than one medicine at the same time can strengthen or weaken the effects of the medicines.</p><p>Especially tell your doctor if you take:</p><p>&bull; diazepam (Valium&reg;)</p><p>&bull; warfarin (Coumadin&reg; Jantoven)</p><p>&bull; phenytoin (Dilantin&reg;)</p><p>&bull; ciclosporin (Gengraf, Neoral, Sandimmune)</p><p>&bull; disulfiram (Antabuse&reg;)</p><p>&bull; a benzodiazepine medicine</p><p>&bull; ketoconazole (Nizoral&reg;)</p><p>&bull; an antibiotic that contains ampicillin</p><p>&bull; products that contain iron</p><p>&bull; digoxin (Lanoxin&reg;)</p><p>&bull; voriconazole (Vfend&reg;)</p><p>&bull; atazanavir (Reyataz&reg;)</p><p>&bull; nelfinavir (Viracept&reg;)</p><p>&bull; tacrolimus (Prograf&reg;)</p><p>&bull; saquinavir (Fortovase&reg;)</p><p>&bull; clarithromycin (Biaxin&reg;, Biaxin XL)</p><p>&bull; clopidogrel (Plavix&reg;)</p><p>&bull; St. John&rsquo;s Wort (Hypericum perforatum)</p><p>&bull; rifampin (Rifater, Rifamate, Rimactane, Rifadin)</p><p>&bull; methotrexate</p><p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</p><p>Know the medicines that you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p><p><strong>OMEPREX PLUS with food and drink</strong></p><p>OMEPREX PLUS should be taken before meals.</p><p><strong>Pregnancy and breast-feeding and fertility</strong></p><p>It is not known if OMEPREX PLUS can harm your unborn baby.</p><p>OMEPREX PLUS can pass into your breast milk and may harm your baby. You and your doctor should decide if you will take OMEPREX PLUS or breastfeed. You should not do both. Talk with your doctor about the best way to feed your baby if you take OMEPREX PLUS.</p><p><strong>Driving and using machines</strong></p><p>OMEPREX PLUS not likely to affect the ability to drive or use machines. Adverse drug reactions such as dizziness and visual disturbances may occur, If affected, patients should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&bull; Take OMEPREX PLUS exactly as prescribed by your doctor.</p><p>&bull; Do not change your dose or stop taking OMEPREX PLUS without talking to your doctor. Take OMEPREX PLUS on an empty stomach at least one hour before a meal.</p><p>&bull; Swallow OMEPREX PLUS Capsules whole with water. Do not use other liquids. Do not crush or chew the capsule. Do not open the capsule and sprinkle contents into food.</p><p>&bull; Do not substitute two 20 mg capsules for one 40 mg capsule of OMEPREX PLUS because you will receive twice the amount of sodium bicarbonate. Talk to your doctor if you have questions.</p><p>&bull; Your doctor may prescribe antibiotic medicines with OMEPREX PLUS to help treat a stomach infection and heal stomach-area (duodenal) ulcers that are caused by bacteria called H. pylori. Make sure you read the patient information that comes with an antibiotic before you start taking it.</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Dose</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr></thead><tbody><tr><td><p>Short-Term Treatment of Active Duodenal Ulcer</p></td><td><p>20 mg</p></td><td><p>Once daily for 4 weeks</p></td></tr><tr><td><p>Benign Gastric Ulcer</p></td><td><p>40 mg</p></td><td><p>Once daily for 4-8 weeks</p></td></tr><tr><td><p>Gastroesophageal Reflux Disease</p><p>(GORD)</p><p>Symptomatic GORD (with no esophageal erosions)</p></td><td><p>20 mg</p></td><td><p>Once daily for up to 4 weeks</p></td></tr><tr><td><p>Erosive Esophagitis</p></td><td><p>20 mg</p></td><td><p>Once daily for 4-8 weeks</p></td></tr><tr><td><p>Maintenance of Healing of&nbsp;Erosive Esophagitis</p></td><td><p>20 mg</p></td><td><p>Once daily</p></td></tr></tbody></table><p><strong>If you take more OMEPREX PLUS than you should</strong></p><p>If you take more capsules than you have been told to take, or if someone else accidentally takes your medicine, contact a doctor, pharmacist or hospital as you may need medical attention.</p><p><strong>If you forget to take OMEPREX PLUS</strong></p><p>If you miss a dose of OMEPREX PLUS, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose at your regular time. Do not take two doses to make up for a missed dose.</p><p>Do not change the prescribed dose by yourself unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, OMEPREX PLUS can cause side effects, although not everybody gets them.</p><p>&bull; Chronic (lasting a long time) inflammation of the stomach lining (Atrophic Gastritis). Taking OMEPREX PLUS for a long period of time may increase the risk of inflammation to your stomach lining. You may or may not have symptoms. Tell your doctor if you have stomach pain, nausea, vomiting, or weight loss.</p><p>&bull; Low magnesium levels in your body. This problem can be serious. Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms of low magnesium.</p><p>Tell your doctor right away if you develop any of these symptoms:</p><p>&bull; seizures</p><p>&bull; dizziness</p><p>&bull; abnormal or fast heartbeat</p><p>&bull; jitteriness</p><p>&bull; jerking movements or shaking (tremors)</p><p>&bull; muscle weakness</p><p>&bull; spasms of the hands and feet</p><p>&bull; cramps or muscle aches</p><p>&bull; spasm of the voice box</p><p>Your doctor may check the level of magnesium in your body before you start taking OMEPREX PLUS, or during treatment if you will be taking OMEPREX PLUS for a long period of time.</p><p><strong>The most common side effects with OMEPREX PLUS include:</strong></p><p>&bull; headache</p><p>&bull; abdominal pain</p><p>&bull; nausea</p><p>&bull; diarrhea</p><p>&bull; vomiting</p><p>&bull; gas</p><p><strong>Other side effects:</strong></p><p>- Serious allergic reactions. Tell your doctor if you get any of the following symptoms with OMEPREX PLUS.</p><p>&bull; Rash</p><p>&bull; face swelling</p><p>&bull; throat tightness</p><p>&bull; difficulty breathing</p><p>Your doctor may stop OMEPREX PLUS if these symptoms happen.</p><p>Using OMEPREX PLUS for a long time may cause problems such as swelling and weight gain. Tell your doctor if this happens.</p><p>If you are on a low-sodium diet or at risk of developing congestive heart failure (CHF), you and your doctor should decide if you will take OMEPREX PLUS.</p><p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p><p>These are not all the possible side effects of OMEPREX PLUS. For more information, ask your doctor or pharmacist.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, Please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of reach and sight of children.</p><p>&bull; Store below 30&deg;C.</p><p>&bull; Keep in the original pack to protect from light and moisture.</p><p>&bull; Do not use OMEPREX PLUS after the expiry date which is stated on the carton. The Expiry date refers to the last day of that month</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are Omeprazole and Sodium Bicarbonate. Each capsule contains Omeprazole 40 mg and Sodium Bicarbonate 1100 mg.</p><p>Excipients : Croscarmelose Sodium , Sodium Stearyl Fumarate, Gelatin Capsule Shell.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Omeprex Plus 40/1100 mg Capsules comes as an Opaque white body/ Opaque white cap with code SJ 06C size 00 gelatin capsule filled with white to off white powder
Pack size:
The capsules are supplied in blisters in a carton pack; containing 30 capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited</p><p>Jeddah &ndash; Kingdom of Saudi Arabia</p><p>&nbsp;</p><p><strong>-To report any side effect (s)</strong></p><p><strong>&bull; Saudi Arabia</strong></p><p>- The National Pharmacovigilance Centre (NPC):</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States and other Countries:</strong></p><p>- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December /2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أوميبركس بلس هو دواء يؤخذ بوصفة طبية ويسمى مثبط لمضخة البروتون.(PPI)</p><p dir="RTL">أوميبركس بلس يقلل من كمية الحمض في المعدة.</p><p dir="RTL">يستخدم أوميبركس بلس للبالغين:</p><p dir="RTL">&bull; لعلاج القرحة في الجزء الأول من الأمعاء الدقيقة (قرحة الإثني عشر) لمدة ٤ أسابيع. قد يصف لك طبيبك ٤ أسابيع أخرى من أوميبركس بلس.</p><p dir="RTL">&bull; لعلاج قرحة المعدة لمدة تصل إلى ٨ أسابيع.</p><p dir="RTL">&bull; لعلاج حرقة المعدة والأعراض الأخرى التي تحدث مع مرض الارتجاع المعدي المريئي (GORD) لمدة تصل إلى ٤ أسابيع. يحدث مرض الارتجاع المعدي المريئي (GORD) عند ارتجاع الحمض من المعدة إلى المريء (الأنبوب الذي يربط الفم بالمعدة). هذا قد يسبب شعور حرق في صدرك أو الحلق، طعم حامضي، أو تجشؤ.</p><p dir="RTL">&bull; للشفاء من الضرر الذي سببه الحمض في بطانة المريء (وتسمى التهاب المريء التآكلي أو EE لمدة تصل إلى ٨ أسابيع).</p><p dir="RTL">للحفاظ على التئام المريء. ومن غير المعروف ما إذا كان أوميبركس بلس آمن وفعال إذا ما تم استخدامه لفترة أطول من ١٢ شهرا (١ سنة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الذئبة الحمامية الجلدية شبه الحادة (</strong><strong>SCLE</strong><strong>)</strong></p><p dir="RTL">ترتبط مثبطات مضخة البروتون مع حالات متكررة جدا من SCLE. في حالة حدوث إصابات وخاصة في المناطق المعرضة للشمس من الجلد. وإذا رافقه ألم مفصلي، ينبغي على المريض طلب المساعدة الطبية فوراً وعلى مقدم الرعاية الصحية المهنية أن يبحث وضع ايقاف هذا الدواء. حدوث SCLE مع علاجات سابقة بمثبطات مضخة البروتون قد تزيد من خطر الاصابة بــ SCLE مع غيرها من مثبطات مضخة البروتون.</p><p dir="RTL"><strong>موانع استعمال أوميبركس بلس</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسية (فرط حساسية) لأوميبرازول أو أي من المكونات الأخرى في أوميبركس بلس (انظر القسم ٦).</p><p dir="RTL">&bull; إذا كنت تعاني من حساسية تجاه أي مثبط لمضخة البروتون.</p><p dir="RTL">الاحتياطات عند تناول أوميبركس بلس</p><p dir="RTL">&bull; إذا قيل لك إن لديك مستويات منخفضة من المغنيسيوم أو الكالسيوم أو البوتاسيوم في الدم.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل في الكبد.</p><p dir="RTL">&bull; إذا كنت تعاني من قصور في القلب.</p><p dir="RTL">&bull; إذا كنت تعاني من متلازمة بارتر (اضطراب الكلى النادر).</p><p dir="RTL">&bull; إذا كان لديك أي نوع من أنواع الحساسية.</p><p dir="RTL">&bull; إذا كنت تعاني من وجود أي حالة طبية أخرى.</p><p dir="RTL">&bull; إذا كنتي حامل أو تخططي لتصبحي حاملا. من غير المعروف ما إذا كان أوميبركس بلس يمكن أن يضر الجنين.</p><p dir="RTL">&bull; إذا كنتي ترضعين طفلك رضاعة طبيعية أو تخططين للرضاعة الطبيعية. يمكن أن يمر أوميبركس بلس إلى حليب الثدي ويضر بطفلك. يجب عليك وعلى طبيبك أن تقررا ما إذا كنتي سوف تتناولين أوميبركس بلس أو ترضعين طفلك رضاعة طبيعية. يجب عدم القيام بالإثنين معا. تحدثي مع طبيبك عن أفضل طريقة لتغذية طفلك إذا كنتي تتناولين أوميبركس بلس.</p><p dir="RTL"><strong>الأدوية الأخرى و أوميبركس بلس</strong></p><p dir="RTL">الرجاء إبلاغ الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، حتى الأدوية الغير وصفية.</p><p dir="RTL">هذا أمر مهم لأن استخدام أكثر من دواء في نفس الوقت يمكن أن يعزز أو يضعف آثار الأدوية.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول:</p><p dir="RTL">&bull; الديازيبام (الفاليوم )</p><p dir="RTL">&bull; الوارفارين (كومادين ،جانتوفين)</p><p dir="RTL">&bull; الفينيتوين (ديلانتين).</p><p dir="RTL">&bull; السيكلوسبورين (جينجراف، نيورال، سانديميون)</p><p dir="RTL">&bull; دايسلفيرام (أنتابوس)</p><p dir="RTL">&bull; دواء يحتوي على البنزوديازيبين</p><p dir="RTL">&bull; كيتوكونازول (نيزورال)</p><p dir="RTL">&bull; مضاد حيوي يحتوي على الأمبيسلين</p><p dir="RTL">&bull; المنتجات التي تحتوي على الحديد</p><p dir="RTL">&bull; ديجوكسين (لانوكسين )</p><p dir="RTL">&bull; فوريكونازول (فيفند)</p><p dir="RTL">&bull; أتازانافير (رياتاز)</p><p dir="RTL">&bull; نلفينافير (فيراسبت )</p><p dir="RTL">&bull; تاكروليموس (بروجراف )</p><p dir="RTL">&bull; ساكينافير (فورتوفيز )</p><p dir="RTL">&bull; كلاريثروميسين (بياكسين ، بياكسين زد ال )</p><p dir="RTL">&bull; كلوبيدوغريل (بلافيكس)</p><p dir="RTL">&bull; نبتة سانت جون (هيبيريكوم بيرفوراتوم )</p><p dir="RTL">&bull; ريفامبين (ريفاتر، ريفامات، ريماكتان، ريفادين)</p><p dir="RTL">&bull; ميثوتريكسيت</p><p dir="RTL">اسأل طبيبك أو الصيدلي عن قائمة بهذه الأدوية، إذا لم تكن متأكدا.</p><p dir="RTL">إعرف أدويتك التي تتناولها. احتفظ بقائمة بها لعرضها على الطبيب والصيدلي عندما تحصل على دواء جديد.</p><p dir="RTL"><strong>تناول أوميبركس بلس مع الطعام والشراب</strong></p><p dir="RTL">يجب تناول كبسولات أوميبركس بلس قبل الوجبات.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">من غير المعروف ما إذا كان أوميبركس بلس يمكن أن يضر الجنين.</p><p dir="RTL">يمكن أن يفرز أوميبركس بلس في حليب الثدي ويضر بطفلك. يجب عليكي وعلى طبيبك أن تقررا ما إذا كنتي سوف تتناولين أوميبركس بلس أو ترضعين طفلك رضاعة طبيعية. يجب عدم القيام بالإثنين معا. تحدثي مع طبيبك عن أفضل طريقة لتغذية طفلك إذا كنتي تتناولين أوميبركس بلس.</p><p dir="RTL"><strong>تأثير أوميبركس بلس على القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس من المرجح أن يؤثر أوميبركس بلس على القدرة على قيادة أو استخدام الآلات. قد تحدث تفاعلات دوائية ضارة مثل الدوخة واضطرابات بصرية ، إذا حدث ذلك، يجب على المرضى عدم القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما قال لك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">&bull; تناول أوميبركس بلس تماما كما هو محدد من قبل الطبيب.</p><p dir="RTL">&bull; لا تغير الجرعة أو تتوقف عن تناول أوميبركس بلس دون التحدث إلى طبيبك. تناول أوميبركس بلس على معدة فارغة قبل ساعة واحدة على الأقل من الوجبة.</p><p dir="RTL">&bull; ابتلع كبسولات أوميبركس بلس كاملة بالماء. لا تستخدم سوائل أخرى. لا تسحق أو تمضغ الكبسولة. لا تفتح الكبسولة وترش المحتويات على الطعام.</p><p dir="RTL">&bull; لا تستبدل ٢ كبسولة ٢٠ ملج لكل كبسولة واحدة ٤٠ ملج من أوميبركس بلس لأنك سوف تتناول كمية بيكربونات الصوديوم مضاعفة. تحدث مع طبيبك إذا كانت لديك أسئلة.</p><p dir="RTL">&bull; قد يصف طبيبك أدوية المضادات الحیویة مع أوميبركس بلس للمساعدة في علاج عدوى المعدة وإلتئام قرحة المعدة (الاثني عشر) التي تسببھا بکتیریا تسمى (H. pylori)(جرثومة المعدة). تأكد من قراءة معلومات المريض التي تأتي مع المضادات الحيوية قبل البدء في تناولها.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p dir="RTL"><strong>دواعي الاستعمال</strong></p></td><td><p dir="RTL"><strong>الجرعة</strong></p></td><td><p dir="RTL"><strong>مدة العلاج</strong></p></td></tr></thead><tbody><tr><td><p dir="RTL">علاج قصير المدى لقرحة الإثني عشر النشطة</p></td><td><p dir="RTL">٢٠ ملج</p></td><td><p dir="RTL">مرة يوميا لمدة ٤ أسابيع</p></td></tr><tr><td><p dir="RTL">قرحة المعدة الحميدة</p></td><td><p dir="RTL">٤٠ ملج</p></td><td><p dir="RTL">مرة يوميا لمدة ٤-٨ أسابيع</p></td></tr><tr><td><p dir="RTL">مرض الارتجاع المعدي المريئي (GORD)</p><p dir="RTL">أعراض (GORD) (مع عدم وجود تآكل المريء)</p></td><td><p dir="RTL">٢٠ ملج</p></td><td><p dir="RTL">مرة يوميا لمدة تصل إلى ٤ أسابيع</p></td></tr><tr><td><p dir="RTL">التهاب المريء التآكلي</p></td><td><p dir="RTL">٢٠ ملج</p></td><td><p dir="RTL">مرة يوميا لمدة ٤-٨ أسابيع</p></td></tr><tr><td><p dir="RTL">الحفاظ على إلتئام المريء التآكلي</p></td><td><p dir="RTL">٢٠ ملج</p></td><td><p dir="RTL">مرة يوميا</p></td></tr></tbody></table><p dir="RTL"><strong>إذا تناولت أوميبركس بلس أكثر مما يجب</strong></p><p dir="RTL">إذا تناولت كبسولات أكثر مما تم وصفه لك، أو إذا كان شخص آخر تناول الدواء عن طريق الخطأ، اتصل بالطبيب أو الصيدلي أو المستشفى لأنك قد تحتاج إلى عناية طبية.</p><p dir="RTL"><strong>إذا نسيت تناول أوميبركس بلس</strong></p><p dir="RTL">إذا نسيت تناول الدواء في أي وقت، تناول الدواء في أقرب وقت تتذكره، إذا حان الوقت لتناول الجرعة المعتادة لا تتناول الجرعة المنسية. تناول الجرعة التالية في وقتها، لا تتناول جرعتين لتعويض الجرعة المنسية.</p><p dir="RTL">لا تغير الجرعة الموصوفة بنفسك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب أوميبركس بلس آثارا جانبية على الرغم من أن هذه الآثار لا تحدث لكل شخص.</p><p dir="RTL">&middot; التهاب مزمن (دائم لفترة طويلة) لبطانة المعدة (التهاب المعدة الضموري ). تناول أوميبركس بلس لفترة طويلة من الزمن قد يزيد من خطر التهاب بطانة المعدة. قد تكون أو لا تكون لديك أعراض. أخبر طبيبك إذا كان لديك ألم في المعدة، غثيان، تقيؤ، أو فقدان الوزن.</p><p dir="RTL">&middot; انخفاض مستويات المغنيسيوم في الجسم. هذه المشكلة يمكن أن تكون خطيرة. انخفاض المغنيسيوم يمكن أن يحدث في بعض الناس الذين يأخذون دواء مثبط لمضخة البروتون لمدة ٣ أشهر على الأقل. إذا حدث انخفاض لمستويات المغنيسيوم، فإنه عادة ما يكون بعد عام من العلاج. قد أو قد لا يكون لديك أعراض انخفاض المغنيسيوم.</p><p dir="RTL">أخبر طبيبك على الفور إذا ظهر أي من هذه الأعراض:</p><p dir="RTL">&bull; نوبات صرع.</p><p dir="RTL">&bull; دوخة.</p><p dir="RTL">&bull; سرعة أو عدم انتظام ضربات القلب.</p><p dir="RTL">&bull; ارتباك.</p><p dir="RTL">&bull; حركات رجعية أو الهز (الهزات).</p><p dir="RTL">&bull; ضعف العضلات.</p><p dir="RTL">&bull; تشنجات اليدين والقدمين.</p><p dir="RTL">&bull; تقلصات أو آلام في العضلات.</p><p dir="RTL">&bull; تشنج الحنجرة.</p><p dir="RTL">طبيبك قد يتحقق من مستوى المغنيسيوم في جسمك قبل البدء في تناول أوميبركس بلس، أو أثناء العلاج إذا كنت سوف تتناول أوميبركس بلس لفترة طويلة من الزمن.</p><p dir="RTL"><strong>الآثار الجانبية الأكثر شيوعا مع أوميبركس بلس ما يلي:</strong></p><p dir="RTL">&bull; صداع الرأس.</p><p dir="RTL">&bull; وجع بطن.</p><p dir="RTL">&bull; غثيان.</p><p dir="RTL">&bull; إسهال.</p><p dir="RTL">&bull; قيء.</p><p dir="RTL">&bull; غازات.</p><p dir="RTL"><strong>الآثار الجانبية الأخرى:</strong></p><p dir="RTL">ردود فعل تحسسية خطيرة. أخبر طبيبك إذا ظهر عليك أي من الأعراض التالية مع أوميبركس بلس.</p><p dir="RTL">&bull; الطفح الجلدي.</p><p dir="RTL">&bull; تورم الوجه.</p><p dir="RTL">&bull; ضيق الحلق.</p><p dir="RTL">&bull; صعوبة في التنفس.</p><p dir="RTL">طبيبك قد يوقف أوميبركس بلس إذا حدثت هذه الأعراض.</p><p dir="RTL">استخدام أوميبركس بلس لفترة طويلة قد يسبب مشاكل مثل التورم وزيادة الوزن. أخبر طبيبك إذا حدث ذلك.</p><p dir="RTL">إذا كنت على نظام غذائي منخفض الصوديوم أو في خطر الإصابة بفشل القلب الاحتقاني، يجب عليك وعلى طبيبك أن تقررا ما إذا كنت سوف تستخدم أوميبركس بلس. أخبر طبيبك إذا كان لديك أي آثار جانبية تزعجك أو لا تختفي. هذه ليست كل الآثار الجانبية المحتملة من أوميبركس بلس. لمزيد من المعلومات، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">إذا أصبحت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يحفظ بعيدا عن متناول أيدي ونظر الأطفال.</p><p dir="RTL">&bull; يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">&bull; يحفظ في العبوة الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">&bull; لا تستخدم أوميبركس بلس بعد تاريخ انتهاء الصلاحية المدون على الشريط وعلى الكرتون. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من هذا الشهر</p><p dir="RTL">&bull; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة في أوميبركس بلس هي أوميبرازول وبيكربونات الصوديوم. تحتوي كل كبسولة على أوميبرازول ٤٠ ملج وبيكربونات الصوديوم ١١٠٠ ملج</p><p dir="RTL">المكونات الأخرى: كروسكارميللوز الصوديوم، فيومارات ستياريل الصوديوم، كبسولة جيلاتينية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أوميبركس بلس عبارة عن جسم أبيض معتم / غطاء أبيض معتم مع رمز&nbsp;SJ 06C&nbsp;حجم&nbsp;00&nbsp;كبسولة جيلاتينية معبأه بمسحوق أبيض إلى أبيض مصفر</p><p dir="RTL"><strong>العبوة</strong>: أوميبركس بلس متوفر في شرائط في عبوة كرتونية؛ تحتوي على ٣٠ كبسولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ساجا الصيدلانية</p><p dir="RTL">الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p dir="RTL">جدة- المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للابلاغ عن الاعراض الجانبية</strong></p><p dir="RTL"><strong>&bull;&nbsp;المملكة العربية السعودية</strong></p><p dir="RTL">- المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">- مركز اتصال هيئة الغذاء والدواء : ١٩٩٩٩</p><p dir="RTL">- البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">- الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;<strong>دول الخليج الأخرى/ الدول الأخرى</strong></p><p dir="RTL">- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر/ ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OMEPREX PLUS®
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient: Omeprazole/sodium bicarbonate 40mg/1100mg For the complete listing of other ingredients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules
Omeprex Plus 40/1100 mg Capsules comes as an Opaque white body/ Opaque white cap with code SJ 06C size 00 gelatin capsule filled with white to off white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Duodenal Ulcer</p><p>Indicated for short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.</p><p>Gastric Ulcer</p><p>Indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer.</p><p>Treatment of Gastroesophageal Reflux Disease (GERD)</p><p>Symptomatic GERD</p><p>Indicated for the treatment of heartburn and other symptoms associated with GERD.</p><p>Erosive Esophagitis</p><p>Is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy</p><p>The efficacy of Omeprex Plus used for longer than 8 weeks in these patients has not been established.</p><p>In the rare instance of a patient not responding to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. If there is recurrence of erosive esophagitis or GERD symptoms (eg, heartburn), additional 4-8 weeks courses of omeprazole may be considered.</p><p>Maintenance of Healing of Erosive Esophagitis</p><p>Indicated to maintain healing of erosive esophagitis. Controlled studies do not extend beyond 12 months.</p><p>Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients</p><p>Indicated for the reduction of risk of upper GI bleeding in critically ill patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Omeprex Plus is available as a capsule for adult use.</strong></p><p>Omeprex Plus should be taken on an empty stomach at least one hour before a meal.</p><p>&nbsp;</p><p>Table 1: Recommended Doses of Omeprex Plus by Indication for Adults 18 Years and Older</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Recommended Dose</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Short-Term Treatment of Active Duodenal Ulcer</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>20 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Once daily for 4 weeks</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Benign Gastric Ulcer</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>40 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Once daily for 4-8 weeks</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Gastroesophageal Reflux Disease (GERD) Symptomatic GERD (with no esophageal erosions)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>20 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Once daily for up to 4weeks</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Erosive Esophagitis</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>20 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Once daily for 4-8 weeks</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Maintenance of Healing of Erosive Esophagitis</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>20 mg</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Once daily</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Administration of Capsules</strong></p><p>OMEPREX PLUS Capsules should be swallowed intact with water. DO NOT USE OTHER LIQUIDS.</p><p>DO NOT OPEN CAPSULE AND SPRINKLE CONTENTS INTO FOOD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OMEPREX PLUS is contraindicated in patients with known hypersensitivity to any components of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticarial .
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy.</p><p>&nbsp;</p><p>Atrophic gastritis</p><p>Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole.</p><p>Acute Interstitial Nephritis</p><p>Acute interstitial nephritis has been observed in patients taking PPIs including OMEPREX PLUS. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue OMEPREX PLUS if acute interstitial nephritis develops.</p><p>Cyanocobalamin (vitamin B-12) Deficiency</p><p>Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.</p><p>Buffer Content</p><p>Each OMEPREX PLUS Capsule contains 1100 mg (13 mEq) of sodium bicarbonate. The total content of sodium in each capsule is 304 mg. The sodium content of OMEPREX PLUS products should be taken into consideration when administering to patients on a sodium restricted diet.</p><p>Because OMEPREX PLUS products contain sodium bicarbonate, they should be used with caution in patients with Bartter&rsquo;s syndrome, hypokalemia, hypocalcemia, and problems with acid base balance. Long-term administration of bicarbonate with calcium or milk can cause milk- alkali syndrome. Chronic use of sodium bicarbonate may lead to systemic alkalosis and increased sodium intake can produce edema and weight increase.</p><p>Clostridium difficile Associated Diarrhea</p><p>Published observational studies suggest that PPI therapy like OMEPREX PLUS may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p><p>Interaction with Clopidogrel</p><p>Avoid concomitant use of OMEPREX PLUS with clopidogrel. Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that interfere with CYP2C19 activity. Concomitant use of clopidogrel with 80 mg omeprazole reduces the pharmacological activity of clopidogrel, even when administered 12 hours apart. When using OMEPREX PLUS , consider alternative anti- platelet therapy.</p><p>Bone Fracture</p><p>Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for</p><p>&nbsp;</p><p>osteoporosis-related fractures should be managed according to the established treatment guidelines.</p><p>Hypomagnesemia</p><p>Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically.</p><p>Concomitant Use of OMEPREX PLUS with St John&rsquo;s Wort or Rifampin</p><p>Drugs which induce CYP2C19 OR CYP34A (such as St John&rsquo;s Wort or rifampin) can substantially decrease omeprazole concentrations. Avoid concomitant use of OMEPREX PLUS with St John&rsquo;s Wort or rifampin.</p><p>Interactions with Investigations for Neuroendocrine Tumors</p><p>Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop omeprazole treatment before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.</p><p>Concomitant Use of OMEPREX PLUS with Methotrexate</p><p>Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients.</p><p>Cutaneous and Systemic Lupus Erythematosus</p><p>Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including omeprazole. These events have occurred as both new onset and an exacerbation of existing autoimmune disease. The majority of PPI-induced lupus erythematous cases were CLE.</p><p>The most common form of CLE reported in patients treated with PPIs was subacute CLE (SCLE) and occurred within weeks to years after continuous drug therapy in patients ranging from infants to the elderly. Generally, histological findings were observed without organ involvement.</p><p>Systemic lupus erythematosus (SLE) is less commonly reported than CLE in patients receiving PPIs. PPI associated SLE is usually milder than non-drug induced SLE. Onset of SLE typically occurred within days to years after initiating treatment in patients ranging from young adults to the elderly. The majority of patients presented with rash; however, arthralgia and cytopenia were also reported.</p><p>Avoid administration of PPIs for longer than medically indicated. If signs or symptoms consistent with CLE or SLE are noted in patients receiving ZEGERID, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most patients improve with</p><p>&nbsp;</p><p>discontinuation of the PPI alone in 4 to 12 weeks. Serological testing (e.g., ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Drugs for Which Gastric pH Can Affect Bioavailability</strong></p><p>Due to its effects on gastric acid secretion, omeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with omeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects). Co-administration of digoxin with OMEPREX PLUS is expected to increase the systemic exposure of digoxin. Therefore, patients may need to be monitored when digoxin is taken concomitantly with OMEPREX PLUS . Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving OMEPREX PLUS and MMF. Use OMEPREX PLUS with caution in transplant patients receiving MMF.</p><p>Drugs Metabolized by Cytochrome P450 (CYP)</p><p>Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time. Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P-450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with OMEPREX PLUS . Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure. Dose adjustment of omeprazole is not normally required. When voriconazole (400 mg every 12 hours for one day, then 200 mg for 6 days) was given with omeprazole (40 mg once daily for 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole. Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased omeprazole serum levels. In a cross-over study in 12 healthy male subjects, St John&rsquo;s wort (300 mg three times daily for 14 days), an inducer of CYP3A4, decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (C-max and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (C-max and AUC decreased by 49.6% and 43.9%, respectively). Avoid</p><p>concomitant use of St. John&rsquo;s Wort or rifampin with omeprazole.</p><p>&nbsp;</p><p>Antiretroviral Agents</p><p>Concomitant administration of atazanavir and proton pump inhibitors is not recommended. Co- administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect. Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg, daily), AUC was decreased by 36% and 92%, C-max by 37% and 89% and C-min by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hours before atazanavir), AUC was decreased by 94%, C-max by 96%, and C- min by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended. Increased Concentration of Saquinavir For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in C-max by 75% and in C-min by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co- administered days 11 to 15. Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole.</p><p>Combination Therapy with Clarithromycin</p><p>Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interaction. Because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs .</p><p>Clopidogrel</p><p>Omeprazole is an inhibitor of CYP2C19 enzyme. Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant administration of OMEPREX PLUS with clopidogrel. When using OMEPREX PLUS , consider use of alternative anti-platelet therapy.</p><p>Tacrolimus</p><p>Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus.</p><p>Interactions With Investigations of Neuroendocrine Tumors</p><p>Drug-induced decrease in gastric acidity results in enterochromaffin-like cell hyperplasia and increased Chromogranin A levels which may interfere with investigations for neuroendocrine tumors.</p><p>Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate</p><p>&nbsp;</p><p>and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.4.&nbsp; Pregnancy</p><p>Category C</p><p><strong><u>Risk Summary</u></strong></p><p>There are no adequate and well-controlled studies on the use of OMEPREX PLUS in pregnant women. Available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use.</p><p>Teratogenicity was not observed in animal reproduction studies with administration of oral esomeprazole magnesium in rats and rabbits with doses about 68 times and 42 times, respectively, an oral human dose of 40 mg (based on a body surface area basis for a 60 kg person). However, changes in bone morphology were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 33.6 times an oral human dose of 40 mg (see Animal Data). Because of the observed effect at high doses of esomeprazole magnesium on developing bone in rat studies, OMEPREX PLUS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p><strong><u>Human Data</u></strong></p><p>Four published epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women exposed to H2 -receptor antagonists or other controls. A population-based retrospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, from 1995-99, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy. The number of infants exposed in utero to omeprazole that had any malformation, low birth weight, low Apgar score, or hospitalization was similar to the number observed in this population. The number of infants born with ventricular septal defects and the number of stillborn infants was slightly higher in the omeprazole-exposed infants than the expected number in this population. A population-based retrospective cohort study covering all live births in Denmark from 1996-2009, reported on 1,800 live births whose mothers used omeprazole during the first trimester of pregnancy and 837, 317 live births whose mothers did not use any proton pump inhibitor. The overall rate of birth defects in infants born to mothers with first trimester exposure to omeprazole was 2.9% and 2.6% in infants born to mothers not exposed to any proton pump inhibitor during the first trimester. A retrospective cohort study reported on 689 pregnant women exposed to either H2 -blockers or omeprazole in the first trimester (134 exposed to omeprazole) and 1,572 pregnant women unexposed to either during the first trimester. The overall malformation rate in offspring born to mothers with first trimester exposure to omeprazole, an H2 -blocker, or were unexposed was 3.6%, 5.5%, and 4.1% respectively. A small prospective observational cohort study followed 113 women exposed to omeprazole during pregnancy (89% first trimester exposures). The reported rate of major congenital malformations was 4% in the omeprazole group, 2% in controls exposed to non-teratogens, and 2.8% in disease-paired controls. Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean</p><p>&nbsp;</p><p>birth weight were similar among the groups. Several studies have reported no apparent adverse short-term effects on the infant when single dose oral or intravenous omeprazole was administered to over 200 pregnant women as premedication for cesarean section under general anesthesia.</p><p><strong><u>Animal Data</u></strong></p><p>Reproductive studies conducted with omeprazole in rats at oral doses up to 138 mg/kg/day (about 33.6 times an oral human dose of 40 mg on a body surface area basis) and in rabbits at doses up to 69 mg/kg/day (about 33.6 times an oral human dose of 40 mg on a body surface area basis) did not disclose any evidence for a teratogenic potential of omeprazole. In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (about 3.36 to 33.6 times an oral human dose of 40 mg on a body surface area basis) produced dose-related increases in embryolethality, fetal resorptions, and pregnancy disruptions. In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138.0 mg/kg/day (about 3.36 to 33.6 times an oral human dose of 40 mg on a body surface area basis). Reproduction studies have been performed with esomeprazole magnesium in rats at oral doses up to 280 mg/kg/day (about 68 times an oral human dose of 40 mg on a body surface area basis) and in rabbits at oral doses up to 86 mg/kg/day (about 42 times an oral human dose of 40 mg on a body surface area basis) and have revealed no evidence of impaired fertility or harm to the fetus due to esomeprazole magnesium. A pre- and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development were performed with the S-enantiomer, esomeprazole magnesium at oral doses of 14 to 280 mg/kg/day (about 3.4 to 68 times an oral human dose of 40 mg of esomeprazole on a body surface area basis). Neonatal/early postnatal (birth to weaning) survival was decreased at doses equal to or greater than 138 mg/kg/day (about 33.6 times an oral human dose of 40 mg on a body surface area basis). Body weight and body weight gain were reduced and neurobehavioral or general developmental delays in the immediate post-weaning timeframe were evident at doses equal to or greater than 69 mg /kg/day (about 16.8 times an oral human dose of 40 mg on a body surface area basis). In addition, decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate and minimal to mild bone marrow hypocellularity were noted at doses of esomeprazole magnesium equal to or greater than 14 mg/kg/day (about</p><p>3.4 times an oral human dose of 40 mg on a body surface area basis). Physeal dysplasia in the femur was observed in offspring of rats treated with oral doses of esomeprazole magnesium at doses equal to or greater than 138 mg/kg/day (about 33.6 times an oral human dose of 40 mg on a body surface area basis). Effects on maternal bone were observed in pregnant and lactating rats in a pre- and postnatal toxicity study when esomeprazole magnesium was administered at oral doses of 14 to 280 mg/kg/day (about 3.4 to 68 times an oral human dose of 40 mg on a body surface area basis). When rats were dosed from gestational day 7 through weaning on postnatal day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses of esomeprazole magnesium equal to or greater than 138 mg/kg/day (about 33.6 times an oral human dose of 40 mg on a body surface area basis). A pre- and post natal development study in rats with esomeprazole strontium (using equimolar doses compared to esomeprazole magnesium study) produced similar results in dams and pups as described above.</p><p>&nbsp;</p><p>Nursing Mothers</p><p>Omeprazole concentrations have been measured in breast milk of a woman following oral administration of 20 mg. The peak concentration of omeprazole in breast milk was less than 7% of the peak serum concentration. The concentration will correspond to 0.004 mg of omeprazole in 200 mL of milk. Because omeprazole is excreted in human milk, because of the potential for serious adverse reactions in nursing infants from omeprazole, and because of the potential for tumorigenicity shown for omeprazole in rat carcinogenicity studies, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. In addition, sodium bicarbonate should be used with caution in nursing mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omeprex Plus not likely to affect the ability to drive or use machines. Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>In the U.S. clinical trial population of 465 patients, the adverse reactions summarized in Table 2 were reported to occur in 1% or more of patients on therapy with omeprazole. Numbers in parentheses indicate percentages of the adverse reactions considered by investigators as possibly, probably or definitely related to the drug.</p><p>Adverse Reactions Occurring In 1% or More of Patients on Omeprazole Therapy</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Omeprazole (n = 465)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>6.9 (2.4)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>3.0 (1.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Abdominal Pain</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>2.4 (0.4)</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Nausea</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>2.2 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>URI</p></td><td style="vertical-align:top"><p>1.9</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>1.5 (0.6)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1.5 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>1.5 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>1.1 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>1.1 (0.2)</p></td></tr><tr><td style="vertical-align:top"><p>Back Pain</p></td><td style="vertical-align:top"><p>1.1</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Tabulated list of adverse reactions</u></strong></p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for omeprazole and post-marketing. None was found to be dose-related. Adverse reactions listed below are classified according to frequency and System Organ Class (SOC). Frequency categories are defined according to the following convention: Very common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt; 1/1,000), Very rare (&lt; 1/10,000), Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>SOC/frequency</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Not known:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hypomagnesaemia; severe hypomagnesaemia may result in hypocalcaemia.</p><p>Hypomagnesaemia may also be associated with hypokalaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Agitation, confusion, depression</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Aggression, hallucinations</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Common:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Dizziness, paraesthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Taste disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Bronchospasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Common:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Dry mouth, stomatitis, gastrointestinal candidiasis</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Not known:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Microscopic colitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Increased liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hepatitis with or without jaundice</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Alopecia, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Not known:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Fracture of the hip, wrist or spine</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Arthralgia, myalgia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Muscular weakness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Interstitial nephritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Gynaecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Malaise, peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Rare:</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Increased sweating</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:71.05pt;margin-top:11.6pt;width:252.55pt;height:92.1pt;z-index:-251658752;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:6.1pt;line-height:13.75pt;
     mso-line-height-rule:exactly'>-The<span style='letter-spacing:-.2pt'> </span>national<span
     style='letter-spacing:-.1pt'> </span>pharmacovigilance<span
     style='letter-spacing:-.15pt'> </span>center<span style='letter-spacing:
     -.1pt'> </span>(NPC):<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:9.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:6.1pt;margin-bottom:.0001pt'>-SFDA<span style='letter-spacing:
     -.75pt'> </span>call<span style='letter-spacing:-.05pt'> </span>center:<span
     style='letter-spacing:-.1pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:9.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:6.1pt;margin-bottom:.0001pt'><span style='letter-spacing:
     -.05pt'>-E-mail:</span><span style='letter-spacing:-.5pt'> </span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:9.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt'><span style='letter-spacing:
     -.05pt'>-Website:</span><span style='letter-spacing:-.5pt'> </span><a
     href="http://ade.sfda.gov.sa/"><span style='color:windowtext;letter-spacing:
     -.05pt;text-decoration:none;text-underline:none'>http://ade.sfda.gov.sa</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="342" height="129" alt="Text Box: -The national pharmacovigilance center (NPC):
-SFDA call center: 19999
-E-mail: npc.drug@sfda.gov.sa
-Website: http://ade.sfda.gov.sa
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience. Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known.</p><p>&nbsp;</p><p>Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.</p><p>As with the management of any overdose, the possibility of multiple drug ingestion should be considered. For current information on treatment of any drug overdose, a certified Regional Poison Control Center should be contacted.</p><p>Single oral doses of omeprazole at 1350, 1339, and 1200 mg/kg were lethal to mice, rats, and dogs, respectively. Animals given these doses showed sedation, ptosis, tremors, convulsions, and decreased activity, body temperature, and respiratory rate and increased depth of respiration. In addition, a sodium bicarbonate overdose may cause hypocalcemia, hypokalemia, hypernatremia and seizures.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: A02BC01, Pharmacotherapeutic group: Proton pump inhibitors.</p><p><strong>&nbsp;</strong></p><p>Mechanism of Action</p><p>Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after rapid disappearance from plasma, omeprazole can be found within the gastric mucosa for a day or more.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of Action</p><p>Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after rapid disappearance from plasma, omeprazole can be found within the gastric mucosa for a day or more.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Croscarmellose Sodium, Sodium Stearyl Fumarate, Hard Gelatin Capsule Shell</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None Known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg; C</p><p>Keep in the original container to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The capsules are supplied in blisters in a carton pack; containing 30 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep all medicine out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceutical
Saudi Arabian Japanese Pharmaceutical Company Limited Jeddah- Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>